AMENDMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN SPARK THERAPEUTICS, INC. AND SENTI BIOSCIENCES, INC.Senti Biosciences, Inc. • August 11th, 2023 • Biological products, (no disgnostic substances)
This Amendment No. 2 (“Amendment”) to the Research Collaboration and License Agreement is made effective as of May 12, 2023 (“Amendment Effective Date”), by and between Spark Therapeutics, Inc. (“Spark”) and Senti Biosciences, Inc. (“Senti”), together, the “Parties.”
